ARVN ▲ +0.8% - Arvinas, Inc.
$ARVN - Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
28-SEP-2026 07:00 AM ET
Share this post
More filings for $ARVN
ARVN ▼ -2.7% - Arvinas, Inc.Sep 3, 2026ARVN ▲ +0.7% - Arvinas, Inc.Sep 1, 2026ARVN - Arvinas, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 15, 2026
View full $ARVN filing history →💬 Comments
Loading comments…
Leave a comment